This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of iTind (intraprostatic temporarily implanted nitinol device) (Olympus Group) for relief of lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH).